Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -24.42 Billion KRW | 5.42% |
| 2022 | -25.82 Billion KRW | -160.72% |
| 2021 | -9.9 Billion KRW | 76.83% |
| 2020 | -42.74 Billion KRW | -152.69% |
| 2019 | 81.12 Billion KRW | 78.43% |
| 2018 | 45.46 Billion KRW | 1314.08% |
| 2017 | -3.74 Billion KRW | -190.55% |
| 2016 | -1.28 Billion KRW | -9998.47% |
| 2015 | 13.02 Million KRW | 0.0% |
| 2013 | -984.92 Million KRW | -52.59% |
| 2012 | -645.48 Million KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -15.43 Billion KRW | 36.81% |
| 2024 Q2 | -9.18 Billion KRW | 40.51% |
| 2023 Q1 | -8.2 Billion KRW | 68.24% |
| 2023 FY | -24.42 Billion KRW | 5.42% |
| 2023 Q4 | -24.42 Billion KRW | -405.36% |
| 2023 Q3 | -4.83 Billion KRW | -6320.36% |
| 2023 Q2 | -75.28 Million KRW | 99.08% |
| 2022 Q3 | 12.08 Billion KRW | 755.05% |
| 2022 Q2 | 1.41 Billion KRW | 33.16% |
| 2022 Q1 | 1.06 Billion KRW | 110.72% |
| 2022 FY | -25.82 Billion KRW | -160.72% |
| 2022 Q4 | -25.82 Billion KRW | -313.69% |
| 2021 Q3 | -121.97 Billion KRW | 1.79% |
| 2021 Q1 | -136.48 Billion KRW | -200.67% |
| 2021 FY | -9.9 Billion KRW | 76.83% |
| 2021 Q2 | -124.2 Billion KRW | 9.0% |
| 2021 Q4 | -9.9 Billion KRW | 91.88% |
| 2020 Q4 | -45.39 Billion KRW | -160.79% |
| 2020 Q3 | 74.67 Billion KRW | -19.64% |
| 2020 Q1 | 73.3 Billion KRW | -6.79% |
| 2020 Q2 | 92.92 Billion KRW | 26.77% |
| 2020 FY | -42.74 Billion KRW | -152.69% |
| 2019 Q1 | 71.34 Billion KRW | 56.92% |
| 2019 FY | 81.12 Billion KRW | 78.43% |
| 2019 Q4 | 78.64 Billion KRW | 103.65% |
| 2019 Q3 | 38.61 Billion KRW | -55.22% |
| 2019 Q2 | 86.23 Billion KRW | 20.88% |
| 2018 Q3 | 54.04 Billion KRW | 1241.89% |
| 2018 Q1 | -4.88 Billion KRW | -30.39% |
| 2018 FY | 45.46 Billion KRW | 1314.08% |
| 2018 Q4 | 45.46 Billion KRW | -15.88% |
| 2018 Q2 | -4.73 Billion KRW | 3.07% |
| 2017 Q4 | -3.74 Billion KRW | 0.0% |
| 2017 FY | -3.74 Billion KRW | -190.55% |
| 2016 FY | -1.28 Billion KRW | -9998.47% |
| 2015 FY | 13.02 Million KRW | 0.0% |
| 2014 Q3 | -981.23 Million KRW | -22.94% |
| 2014 Q2 | -798.17 Million KRW | 27.07% |
| 2014 Q1 | -1.09 Billion KRW | -11.12% |
| 2013 Q3 | -1.2 Billion KRW | -7009.04% |
| 2013 Q1 | 1.37 Billion KRW | 313.07% |
| 2013 Q2 | 17.38 Million KRW | -98.74% |
| 2013 Q4 | -984.92 Million KRW | 18.01% |
| 2013 FY | -984.92 Million KRW | -52.59% |
| 2012 FY | -645.48 Million KRW | 0.0% |
| 2012 Q4 | -645.48 Million KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 47.111% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 39.815% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 153.864% |
| Bioneer Corporation | -3.9 Billion KRW | -525.054% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 392.462% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 264.88% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 371.642% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 106.28% |
| Medy-Tox Inc. | 49.58 Billion KRW | 149.261% |
| Peptron, Inc. | 4.86 Billion KRW | 601.697% |
| Amicogen, Inc. | 125.26 Billion KRW | 119.5% |
| Genexine, Inc. | 61.39 Billion KRW | 139.784% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | -78.463% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 56.424% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 145.596% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 25.844% |
| SillaJen, Inc. | -13.89 Billion KRW | -75.831% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 128.982% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 189.227% |
| Genomictree Inc. | -43.43 Billion KRW | 43.765% |
| MedPacto, Inc. | -64 Billion KRW | 61.835% |
| D&D Pharmatech | -7.5 Billion KRW | -225.338% |
| EASY BIO,Inc. | 53.21 Billion KRW | 145.904% |
| GI Innovation, Inc. | -4.82 Billion KRW | -406.496% |